Skip to main content
Nanologica logo

Nanologica — Investor Relations & Filings

Ticker · NICA ISIN · SE0005454873 LEI · 54930017L41C7P87LP22 ST Manufacturing
Open in API
Filings indexed 181 across all filing types
Latest filing 2024-10-31 Declaration of Voting R…
Country SE Sweden
Listing ST NICA

About Nanologica

https://nanologica.com/

Nanologica is a life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. The company specializes in nanoporous silica particles for preparative chromatography, a critical step in drug production. Its core product, NLAB Saga®, is a spherical, porous silica media engineered for the large-scale purification of peptide drugs, such as insulin and GLP-1 analogues used to treat diabetes and obesity. The product's high mechanical and chemical stability provides effective purification and a long lifetime, which increases productivity and reduces costs for pharmaceutical manufacturers. Nanologica's mission is to lower the manufacturing costs of these drugs, thereby increasing patient access to life-saving treatments. The company is also developing a broader portfolio of purification media.

Recent filings

Filing Released Lang Actions
Number of Shares and Votes in Nanologica AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly discusses a change in the number of registered shares and votes following the registration of a rights issue. It details the increase in shares and share capital as of October 31, 2024. This content directly relates to changes in the company's capital structure and share count. This aligns best with the 'Share Issue/Capital Change' definition (SHA). Although it mentions a rights issue (a financing activity, CAP), the core focus is the resulting change in the total number of shares, making SHA the most precise fit. The document is short and includes an attachment link, but the content itself is a substantive announcement about share count changes, not just a notice that a report is attached, thus ruling out RPA/RNS based on the 'MENU VS MEAL' rule for this specific content type.
2024-10-31 English
Nanologica's Rights Issue Registered - Conversion of BTU to Shares and warrants
Share Issue/Capital Change Classification · 100% confidence The document is a press release from Nanologica AB announcing the registration of a rights issue with the Swedish Companies Registration Office and the subsequent conversion of paid subscribed units (BTU) into shares and warrants. This relates directly to changes in the company's capital structure and share issuance. According to the provided definitions, announcements regarding new share issues or capital changes fall under the 'SHA' category.
2024-10-30 English
Nanologicas företrädesemission registrerad – omvandling av BTU till aktier och teckningsoptioner
Share Issue/Capital Change Classification · 100% confidence The document is a press release announcing the registration of a rights issue (företrädesemission) and the subsequent conversion of paid subscribed units (BTU) into shares and warrants. This falls under the category of capital changes and share issuance. While it mentions a PDF attachment, the content itself is a formal announcement of a corporate action regarding share capital structure, which is best classified as a share issue/capital change announcement.
2024-10-30 Swedish
Nanologica offentliggör utfall i företrädesemission
Capital/Financing Update Classification · 98% confidence The document is a press release titled "Nanologica offentliggör utfall i företrädesemission" (Nanologica announces outcome of rights issue). It details the subscription rate, the amount raised (approx. 99.4 MSEK), the use of guarantee commitments, the impact on the number of shares, and information about attached warrants (TO 2024/2025). This content directly relates to a corporate financing activity, specifically the conclusion of a rights issue (a form of capital raising). This aligns perfectly with the definition for Capital/Financing Update (CAP). Although it is a press release, the core subject matter is the financing event itself, not just the announcement of a report's publication (RPA) or a general regulatory filing (RNS).
2024-10-16 Swedish
Nanologica Announces Outcome of Rights Issue
Capital/Financing Update Classification · 98% confidence The document is a press release titled "Nanologica Announces Outcome of Rights Issue." It details the subscription rate, proceeds, allotment process, and impact on share capital resulting from a rights issue (a form of fundraising/capital structure change). This directly corresponds to the definition of a Capital/Financing Update (CAP). Although it announces the outcome of a corporate action, it is not a general regulatory filing (RNS) or a report itself (like 10-K or IR). The core subject is the financing activity.
2024-10-16 English
Nanologica offentliggör tilläggsprospekt avseende företrädesemission
Report Publication Announcement Classification · 95% confidence The document is a press release from Nanologica AB announcing the publication of a 'supplementary prospectus' (tilläggsprospekt) related to an ongoing rights issue (företrädesemission). The text explicitly states that the document is an announcement regarding the approval and availability of this supplement, directing readers to the company's website for the full document. Following the 'Menu vs Meal' rule, this is an announcement of a report/filing rather than the filing itself, making it a Report Publication Announcement (RPA).
2024-10-08 Swedish

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.